Skip To Main Content
Chen Xiaolin on Muck Rack

Chen Xiaolin

As seen in: British Pharmacological Society, Lexology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Chen Xiaolin’s profile

Articles by Chen Xiaolin

Bleomycin overdose in a patient with stage II Hodgkin lymphoma: A case report of a medication error

|
By Chen Xiaolin, Yang Hai, Zhang Jieting, Xue Shuyi
| British Pharmacological Society
CONFLICT OF INTEREST STATEMENT None. Supporting Information Filename Description bcp15744-sup-0001-Supporting information-BJCP-20230320.docxWord 2007 document , 705 KB DATA S1 Supporting information REFERENCES 1, , , . Bleomycin-induced flagellate erythema after venous malformation sclerosis—case report and brief review. Pediatr Dermatol. 2018; 35(1): e5-e8. doi:10.1111/pde.13297 2, . Medical errors. Dosage nomenclature of bleomycin needs to be standardised to avoid errors. BMJ.
Open in Who Shared Issue with article?

注册制背景下私有化及红筹回归企业如何面对中国证券监管机构问询解析 - Lexology

|
By Peng Cheng, Lin Zhijun, Wu Yuanbin, Chen Xiaolin, Qiu Yuxia
| Lexology Verified
引言 2020年4月27日中央全面深化改革委员会通过《创业板改革并试点注册制总体实施方案》，随后中国证监会和深圳证券交易所同步发布相关规则的征求意见稿，再次点燃了上一轮科创板推出引发的注册制热点讨论。与此同时，因国内外资本市场的变化，众多红筹架构的公司（包括已经上市的中概股），也在把回归国内资本市场作为当下的重要选项。但是因为国内和国外资本市场监管规则和审核思路的差异，红筹架构企业和国内企业股东诉求的差异，当回归与否的决策落到企业自己头上，就是一个无比重大和难以抉择的事项。 我们团队在国内资本市场业务方面专注于红筹回归企业的境内上市，从2013年开始就服务大批红筹企业回归国内资本市场的上市。本文希望把我们这几年参与红筹回归项目时和中国证监会和上海证券交易所（“监管机构”）的沟通过程中理解到的监管思路做一个简单梳理总结，与读者分享。 我们在2017年完成人力资源第一股科锐国际（股票代码：300662）红筹回归上市后撰写了《分解复杂红筹回归IPO项目 把脉证监会最新监管要求》https://mp.weixin.qq.com/s/yIz5fnU_Jb69HvTYh-abJg...
Open in Who Shared Issue with article?
Show More